HOUSTON, TX / ACCESSWIRE / June 6, 2022 / Vertex Energy, Inc. (NASDAQ:VTNR) ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, today announced it ...

Vertex saw disappointments in 2022, that may be about to change. Profitability may improve as onerous hedging rolled off for Q4. Shares could double from here to around $18 on my estimates (range: $10 ...

The US Food and Drug Administration (FDA) has accepted Vertex Pharmaceuticals’ completed new drug application (NDA) submission for suzetrigine, as the company’s non-opioid-based treatment for acute ...

On Monday, Goldman Sachs reaffirmed a Buy rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ:VRTX), with a set price target of $598.00. At a recent event, Vertex presented ...

Vertex Pharmaceuticals has a dominant Cystic fibrosis franchise and plans to launch five new products by 2028, including a next-generation CF drug and a non-opioid pain management drug. VRTX stock has ...

VENTURE capital firm Vertex Ventures, backed by Singapore state investor Temasek, is set to raise nearly US$500 million for a new fund that will invest in efforts to step up China’s domestic tech ...